Mylan Pursues ‘Market First’ Playbook, Partners Lupin For Enbrel Biosimilar

Mylan has struck a deal to commercialize Lupin's biosimilar Enbrel (etanercept), continuing to seize opportunities beyond existing alliances to ensure an early play in certain key markets. Longstanding Mylan partner Biocon maintains that it won't lose out either, though the outlook for their partnered etanercept is unclear, at least for now.